Covered recipient · General Payments record
DAVID JAY COHEN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$540,258.48
558 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $444,239.97 | 112 |
| Travel and Lodging | $48,679.01 | 122 |
| Consulting Fee | $14,755.00 | 4 |
| Food and Beverage | $13,763.10 | 311 |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,826.00 | 3 |
| Honoraria | $7,800.00 | 2 |
| Education | $195.40 | 4 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $121,393.92 | 124 |
| Regeneron Healthcare Solutions, Inc. | $93,485.25 | 70 |
| Janssen Biotech, Inc. | $68,399.37 | 60 |
| GENZYME CORPORATION | $58,300.68 | 32 |
| UCB, Inc. | $51,597.53 | 59 |
| Galderma Laboratories, L.P. | $33,836.81 | 47 |
| Lilly USA, LLC | $32,154.39 | 36 |
| Incyte Corporation | $22,898.28 | 31 |
| PFIZER INC. | $16,546.09 | 12 |
| Amgen Inc. | $15,905.29 | 16 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14,816.60 | 20 |
| Organon LLC | $9,526.52 | 15 |
| Novartis Pharmaceuticals Corporation | $391.52 | 12 |
| REVANCE THERAPEUTICS, INC. | $267.30 | 2 |
| Organogenesis Inc. | $170.62 | 5 |
| Kerecis Limited | $140.01 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $97.13 | 1 |
| Arcutis Biotherapeutics, Inc. | $81.91 | 4 |
| Janssen Scientific Affairs, LLC | $66.97 | 1 |
| LEO Pharma Inc. | $52.67 | 3 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $46.51 | 2 |
| MAYNE PHARMA COMMERCIAL LLC | $33.35 | 1 |
| Sanara MedTech Inc. | $19.02 | 1 |
| KYOWA KIRIN, INC. | $17.57 | 1 |
| Janssen Pharmaceuticals, Inc | $13.17 | 1 |
Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID JAY COHEN
NPI 1487652020 · CMS profile ID 158374
Allopathic & Osteopathic Physicians / Dermatology
MACON, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID JAY COHEN, NPI 1487652020, CMS profile ID 158374. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). DAVID JAY COHEN, NPI 1487652020, CMS profile ID 158374. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- DAVID JAY COHEN, NPI 1487652020, CMS profile ID 158374, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 12 of 12; records 551–558 of 558 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1487652020?year=2025&recipient=provider&page=12#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
558 matching records · $540,258.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 551–558 of 558.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $40.88 | 01/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422532 | CMS |
| UCB, Inc. | $58.74 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422534 | CMS |
| UCB, Inc. | $65.00 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422536 | CMS |
| UCB, Inc. | $85.00 | 01/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422538 | CMS |
| UCB, Inc. | $127.23 | 01/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422540 | CMS |
| UCB, Inc. | $333.16 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422542 | CMS |
| UCB, Inc. | $636.95 | 01/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224422544 | CMS |
| Regeneron Healthcare Solutions, Inc. | $8,967.00 | 01/01/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212892919 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $350,254.20 | 48 |
| PY2024 | Principal investigator | $274,007.04 | 102 |
| PY2023 | Principal investigator | $255,431.31 | 95 |
| PY2022 | Recipient | $480.08 | 2 |
| PY2022 | Principal investigator | $124,993.10 | 42 |
| PY2021 | Recipient | $1,652.03 | 3 |
| PY2021 | Principal investigator | $481,218.52 | 59 |
| PY2020 | Recipient | $3,012.86 | 7 |
| PY2020 | Principal investigator | $518,166.62 | 80 |
| PY2019 | Recipient | $13,664.30 | 6 |
| PY2019 | Principal investigator | $648,880.49 | 72 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
48 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,519.00 | 12/22/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226127468 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,489.00 | 12/08/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226127464 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $695.81 | 12/04/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184269237 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,665.00 | 12/01/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175390521 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,920.00 | 11/17/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226127461 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,478.00 | 10/27/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226127457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $107.72 | 10/23/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252626 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,016.83 | 10/03/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190307243 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,907.39 | 10/03/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184244669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,390.00 | 10/02/2025 | Non-covered Recipient Entity Dermatologic Surg Specialists PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175208748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,509.00 | 09/04/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175390501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,875.00 | 09/04/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175390514 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $27,759.00 | 09/03/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226127448 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $722.47 | 08/14/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184228319 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,423.00 | 08/11/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127453 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,826.00 | 08/04/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226127444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $807.90 | 07/17/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217076 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,758.00 | 07/14/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226127434 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,853.60 | 07/14/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127440 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $438.91 | 06/12/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH BULLOUS PEMPHIGOID | No dispute reported | 06/30/2026 | 1184206261 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,556.00 | 06/09/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127427 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $25,423.50 | 05/19/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,045.63 | 05/15/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184194637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,105.00 | 04/28/2025 | Non-covered Recipient Entity Dermatologic Surg Specialists PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175209022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 04/23/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184189185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $232.50 | 04/23/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184189187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 04/23/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184189191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,614.60 | 04/15/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184183412 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $874.06 | 04/09/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190307247 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,800.00 | 04/02/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226127417 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,399.00 | 04/02/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127425 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $59,849.52 | 03/31/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190307245 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,132.00 | 03/27/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175390507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,207.21 | 03/11/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184170866 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,185.50 | 03/10/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127423 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,074.00 | 03/06/2025 | Non-covered Recipient Entity Dermatologic Surg Specialists PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175208555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,131.00 | 03/06/2025 | Non-covered Recipient Entity Dermatologic Surg Specialists PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175208692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,000.00 | 03/06/2025 | Non-covered Recipient Entity Dermatologic Surg Specialists PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175209220 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,212.00 | 03/03/2025 | Non-covered Recipient Entity Dermatologic Surg Specialists PC | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175208942 |
| Principal investigator 1 | Eli Lilly and Company | $9,375.60 | 02/25/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGICAL SPECIALISTS | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187882472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,541.77 | 02/25/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155412 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,743.60 | 02/24/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226127414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155078 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 02/18/2025 | Non-covered Recipient Entity Skin Care Physicians Of Georgia | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226127410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,961.25 | 01/17/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148123 |
| Principal investigator 1 | Eli Lilly and Company | $10,751.15 | 01/07/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGICAL SPECIALISTS | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187878189 |
| Principal investigator 1 | Eli Lilly and Company | $5,517.35 | 01/07/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGICAL SPECIALISTS | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR | No dispute reported | 06/30/2026 | 1187878727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $161.58 | 01/07/2025 | Non-covered Recipient Entity DERMATOLOGIC SURGERY SPECIALISTS PC | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184145856 |